Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical tacrolimus added to systemic therapy for skin involvement in idiopathic granulomatous mastitis
IRCT20230822059222N2Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tacrolimus in Granulomatous lobular mastitis (GLM) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Disappearance of inflammatory signs, Closure of fistula orifices and 1 more. Started Apr 2024; status: completed.
02
Drugs
tacrolimus
03
Conditions
Granulomatous lobular mastitis (GLM)
Beyond the preview
Go deeper on IRCT20230822059222N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230822059222N2.